13.2 Trinucleotide Repeat Expansion Disorders
Key Takeaways
- Trinucleotide repeat expansion disorders result from dynamic, unstable microsatellite expansions that increase across successive generations, driving genetic anticipation (earlier onset and greater clinical severity).
- Fragile X syndrome is caused by a (CGG)n expansion in the 5' UTR of FMR1; alleles with >200 repeats (full mutation) undergo promoter hypermethylation and transcriptional silencing, abolishing FMRP expression.
- FMR1 premutation alleles (55-200 CGG repeats) produce elevated, toxic FMR1 mRNA, conferring clinical risks for Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) and Fragile X-Associated Primary Ovarian Insufficiency (FXPOI).
- Huntington disease is a fully penetrant autosomal dominant polyglutamine (polyQ) neurodegenerative disorder caused by a coding (CAG)n repeat expansion (>=40 repeats) in exon 1 of HTT, showing pronounced paternal transmission expansion bias.
- Repeat-Primed PCR (RP-PCR) utilizes locus-specific, repeat-hybridizing, and universal tail primers to generate a diagnostic electropherogram ladder, overcoming standard PCR sizing limits for large expansions.
13.2 Trinucleotide Repeat Expansion Disorders
Quick Summary: Trinucleotide repeat disorders are caused by dynamic mutations—unstable microsatellite tandem repeat tracts that expand during gametogenesis and somatic cell division. Unlike static Mendelian point mutations, unstable repeat alleles expand in size over generations, leading to genetic anticipation (earlier age of onset and increased disease severity in successive generations). Key pathogenic mechanisms include promoter hypermethylation and transcriptional silencing (FMR1 in Fragile X syndrome), toxic polyglutamine (polyQ) protein gain-of-function (HTT in Huntington disease, ATXN1-3 in spinocerebellar ataxias), toxic RNA-mediated spliceopathy (DMPK in Myotonic Dystrophy Type 1), and heterochromatin-mediated transcriptional elongation block (FXN in Friedreich Ataxia). Accurate molecular diagnostic sizing requires combining Capillary Electrophoresis (CE), Repeat-Primed PCR (RP-PCR), Methylation-Specific PCR (MS-PCR), and Southern Blot analysis.
1. Mechanisms of Dynamic Repeat Instability & Genetic Anticipation
MECHANISM OF REPEAT EXPANSION VIA STRAND SLIPPAGE
Replication Fork Stalling & Polymerase Slippage on Lagging Strand:
Template Strand: 5'---[ CAG ][ CAG ][ CAG ][ CAG ][ CAG ][ CAG ]---3'
| | | | | |
Nascent Strand: 3'---[ GTC ][ GTC ] [ GTC ][ GTC ][ GTC ][ GTC ]---5'
\ /
[ GTC ] <-- Hairpin / Loop Formation
[ GTC ] (Slip-Stranded Intermediate)
|
v
DNA Repair Failure (MSH2/MSH3)
|
v
Next Cycle: Duplicated Repeat Tract!
(Expansion Inherited by Progeny)
Molecular Drivers of Instability
- Replication Slippage: During DNA lagging-strand synthesis, repetitive trinucleotide tracts form stable secondary structures (hairpins, quadruplexes, or slipped-strand loops). DNA polymerase stalls and slips backward, re-copying previously synthesized repeat units.
- Mismatch Repair (MMR) Interplay: Instead of correcting slip-stranded loops, mismatch repair recognition complexes (especially MutS$\beta$, composed of MSH2 and MSH3) aberrantly stabilize the loop structures and promote repeat expansion during error-prone base/mismatch excision.
- Parental Transmission Bias:
- Maternal Expansion Bias: In Fragile X syndrome (FMR1) and Myotonic Dystrophy (DMPK), massive repeat expansions occur almost exclusively during maternal oogenesis.
- Paternal Expansion Bias: In Huntington disease (HTT) and Spinocerebellar Ataxias, dramatic expansions (leading to juvenile-onset forms) occur predominantly during paternal spermatogenesis.
2. Fragile X Syndrome & The FMR1 Premutation Spectrum
Fragile X syndrome is the most common inherited cause of intellectual disability and autism spectrum disorder in males ($1\text{ in }4,000\text{ males}$; $1\text{ in }8,000\text{ females}$). It is caused by an expansion of a $(CGG)_n$ repeat in the 5' Untranslated Region (5' UTR) of the FMR1 gene on chromosome Xq27.3.
+----------------------------------------------------------------------------------------------------+
| FMR1 ALLELE CLASSIFICATION SPECTRUM |
+-------------------+-------------------+-------------------+----------------------------------------+
| Allele Category | CGG Repeat Count | Methylation & RNA | Clinical Phenotype & Transmission Risk |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Normal** | **5 to 44 repeats**| Unmethylated; | Normal cognitive phenotype; |
| | (Mean $\sim 29–30$)| Normal FMRP levels| AGG interruptions maintain stability |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Intermediate / | **45 to 54 repeats**| Unmethylated; | Normal phenotype; minimal risk of |
| Gray Zone** | | Normal FMRP levels| expansion to full mutation in 1 gen |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Premutation** | **55 to 200 | Unmethylated; | **Elevated FMR1 mRNA (toxic)**; |
| | repeats** | **$\uparrow$ mRNA (2-8x)**| Risk of **FXTAS** in aging males; |
| | | Mild $\downarrow$ FMRP| Risk of **FXPOI** in females; |
| | | | Unstable upon maternal transmission |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Full Mutation** | **> 200 repeats** | **Hypermethylated | **Fragile X Syndrome**: Intellectual |
| | (often 500-2000+) | CpG islands**; | disability, macroorchidism, long face, |
| | | **Transcriptional | large ears, autistic behaviors; zero |
| | | Silencing (No FMRP)| FMRP expression |
+-------------------+-------------------+-------------------+----------------------------------------+
FMR1 TRANSCRIPTIONAL SILENCING MECHANISM
Normal FMR1 Allele (CGG ~30): [ Unmethylated CpG ]---(CGG)30---> [ Active Transcription ] -> FMRP Made
(Brain Synaptic Function)
Full Mutation (>200 CGG): [ Hypermethylated ]====(CGG)n====> [ Transcriptional Block! ] -> NO FMRP
[ Me-CpG Islands ] [ Chromatin Condensation] (Fragile X Phenotype)
FMR1 Premutation-Associated Pathologies
Unlike full mutations, premutation alleles do not silence transcription. Instead, premutation alleles exhibit 2- to 8-fold elevated levels of mutant FMR1 mRNA, leading to an RNA-mediated gain-of-function toxicity:
- Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Late-onset neurodegenerative disorder occurring in $\sim 40–50%$ of male premutation carriers over age 50, characterized by progressive intention tremor, cerebellar ataxia, parkinsonism, and intranuclear neuronal inclusions.
- Fragile X-Associated Primary Ovarian Insufficiency (FXPOI): Occurs in $\sim 20–25%$ of female premutation carriers, causing hypergonadotropic hypogonadism, irregular menses, and premature menopause before age 40.
The Stabilizing Role of AGG Interruptions
Within the normal FMR1 CGG repeat tract, AGG trinucleotide interruptions typically occur every 9 to 10 repeats (e.g., $(CGG)_9AGG(CGG)_9AGG(CGG)_n$). These AGG triplets anchor DNA polymerase and prevent hairpin formation during replication. The loss of AGG interruptions markedly increases the probability of intergenerational expansion from a premutation to a full mutation.
3. Huntington Disease (HTT) & Polyglutamine (PolyQ) Neurodegeneration
Huntington disease (HD) is an autosomal dominant, progressive neurodegenerative disorder characterized by involuntary choreiform movements, psychiatric disturbances, and cognitive decline. It is caused by an expanded $(CAG)_n$ repeat in exon 1 of the HTT (huntingtin) gene on chromosome 4p16.3.
+----------------------------------------------------------------------------------------------------+
| HUNTINGTON DISEASE CAG REPEAT STRATA |
+-------------------+-------------------+-------------------+----------------------------------------+
| Allele Category | CAG Repeat Count | Clinical Outcome | Inheritance & Anticipation Dynamics |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Normal** | **$\le 26$ CAG** | Unaffected | Stable across generations |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Intermediate** | **27 to 35 CAG** | Unaffected | Mutable; risk of expanding into disease|
| | | | range during **paternal transmission** |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Reduced | **36 to 39 CAG** | Incompletely | May or may not develop symptoms during |
| Penetrance** | | Penetrant | normal lifespan; 50% transmission risk |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Full | **$\ge 40$ CAG** | **100% Penetrant | Inevitable clinical onset; inverse |
| Penetrance** | | Huntington Dis.** | relationship between repeat length & age|
+-------------------+-------------------+-------------------+----------------------------------------+
| **Juvenile HD** | **$\ge 60$ CAG** | **Onset < 20 yrs**| Severe rigidity, seizures, rapid loss; |
| | | | Almost exclusively paternally inherited|
+-------------------+-------------------+-------------------+----------------------------------------+
TOXIC POLYGLUTAMINE ONCOGENESIS IN HUNTINGTON
Mutant HTT Exon 1 mRNA: 5'---[ AUG ]===(CAG)40-100+===[ Rest of HTT ]---3'
|
Translation
v
Mutant HTT Oncoprotein: N-term---[ PolyQ Tract (40-100+ Gln residues) ]---C-term
|
Protein Misfolding
v
Intranuclear Aggregates & Soluble Oligomers in Striatal Medium Spiny Neurons
-> Transcriptional Dysregulation (CBP/p300 Sequestration)
-> Mitochondrial Dysfunction & Excitotoxicity
-> Selective Apoptosis of Caudate and Putamen Neurons
4. Myotonic Dystrophy (DM1/DM2) & Friedreich Ataxia (FRDA)
+----------------------------------------------------------------------------------------------------+
| COMPARATIVE CLINICAL GENETICS OF REPEAT EXPANSION DISORDERS |
+-------------------+-------------------+-------------------+----------------------------------------+
| Disease & Gene | Repeat Unit & | Inheritance Mode | Pathophysiology & Hallmark Symptoms |
| (Locus) | Genomic Location | & Thresholds | |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Myotonic | **(CTG)$_n$** | **Autosomal | **Toxic RNA Gain-of-Function**; mutant |
| Dystrophy 1** | **3' UTR** of | **Dominant** | CUG transcripts sequester **MBNL1** |
| *DMPK* (19q13.3) | *DMPK* gene | Normal: 5–34 | splicing factor -> Aberrant splicing of|
| | | Premutation: 35–49| *CLCN1* (myotonia), *INSR* (insulin |
| | | Classic: 50–1000 | resistance), *TNNT2* (cardiac block); |
| | | Congenital: >1000 | Congenital DM1: severe hypotonia/death |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Myotonic | **(CCTG)$_n$** | **Autosomal | Proximal muscle weakness, myotonia, |
| Dystrophy 2** | **Intron 1** of | **Dominant** | cataracts; milder than DM1, no severe |
| *CNBP* (3q21.3) | *CNBP* (*ZNF9*) | Expansion up to | congenital form |
| | | 11,000+ repeats | |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Friedreich | **(GAA)$_n$** | **Autosomal | **Loss of Frataxin Expression**; sticky|
| Ataxia (FRDA)** | **Intron 1** of | **Recessive** | non-B DNA triplex / R-loops impede |
| *FXN* (9q21.1) | *FXN* gene | Normal: 5–33 | RNA polymerase II elongation -> |
| | | Disease: 66–1700 | Mitochondrial iron overload, sensory |
| | | | ataxia, hypertrophic cardiomyopathy |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Spinocerebellar | **(CAG)$_n$** | **Autosomal | Polyglutamine neurodegeneration; |
| Ataxias (SCA)** | Exonic Coding | **Dominant** | Progressive cerebellar ataxia, dys- |
| (SCA1, 2, 3, 6, 7)| (PolyQ) | Varies by subtype | arthria, oculomotor abnormalities |
+-------------------+-------------------+-------------------+----------------------------------------+
5. Diagnostic Methodologies for Repeat Expansions
Standard PCR across expanded repetitive elements fails due to extreme GC content, secondary structure formation, and polymerases stalling over thousands of base pairs. Clinical laboratories deploy specialized multimodal assay configurations:
REPEAT-PRIMED PCR (RP-PCR) ARCHITECTURE
Gene-Specific Primer (P1-FAM) Repeat-Binding Primer (P3-Tail + (CTG)5)
5'--[ FLUORESCENT ]---------------------> <-------------------[ TAIL SEQUENCE ]--5'
5'========================[ CTG ][ CTG ][ CTG ][ CTG ][ CTG ][ CTG ]========================3'
<-------------------[ TAIL SEQUENCE ]--5' (P2 Universal Tail)
Result on Capillary Electrophoresis:
Fluorescence
^
| || || || || || || || || || || .. .. .. <-- Diagnostic Continuous Tooth Ladder
| || || || || || || || || || || (Spans Beyond High-Molecular Limit!)
+--------------------------------------------------> Fragment Size (bp)
+----------------------------------------------------------------------------------------------------+
| TRINUCLEOTIDE REPEAT TESTING PLATFORMS COMPARISON |
+-------------------+-------------------+-------------------+----------------------------------------+
| Technology | Analytical Target | Sizing Capability | Diagnostic Role & Advantages |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Standard PCR & | Flanking primers | Exact sizing up to| Rapid, precise sizing for normal and |
| Capillary Elect.**| amplify full tract| $\sim 100–150$ rep| small premutation alleles; drops out |
| | | | completely on large full mutations |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Repeat-Primed | Triple-primer mix | Qualitative ladder| Unambiguously flags full expansions of |
| PCR (RP-PCR)** | (Gene, Repeat, Tail)| up to >1,000 rep | any size; characteristic decay pattern;|
| | | | detects presence even if dropped out |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Methylation- | Bisulfite or | Methylated vs | Quantifies promoter silencing in |
| Specific PCR** | methylation-sens. | unmethylated ratio| *FMR1*; differentiates premutation from|
| | digestion + PCR | | full mutation without Southern blot |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Southern Blot | Restriction digest| Sizes massive | Historical gold standard for *FMR1* and|
| Analysis** | (*EcoRI* + *EagI*)| expansions up to | *DMPK*; confirms methylation mosaicism;|
| | + labeled probe | several kilobases | labor-intensive with long turnaround |
+-------------------+-------------------+-------------------+----------------------------------------+
A 58-year-old grandfather of a boy diagnosed with Fragile X syndrome presents with progressive intention tremors and cerebellar ataxia. Molecular testing of the grandfather's FMR1 gene reveals 95 CGG repeats with an unmethylated promoter. What is the molecular diagnosis and underlying mechanism responsible for this grandfather's neurological symptoms?
A diagnostic genetics laboratory performs FMR1 testing on a female infant with developmental delay. Standard flanking PCR followed by capillary electrophoresis demonstrates a single prominent fluorescent peak corresponding to 30 CGG repeats. Why is standard PCR alone insufficient to rule out Fragile X syndrome in this patient, and what reflex assay must be performed?
In Huntington disease testing, how is an HTT exon 1 allele containing 38 CAG repeats classified, and what is its clinical significance regarding disease transmission and penetrance?